Novomics Co., Ltd. (XKON:283100)
South Korea · Delayed Price · Currency is KRW 45.00
+13.00 (40.63%)
Inactive · Last trade price on May 27, 2025
Novomics Company Description
Novomics Co., Ltd. designs and develops genetic molecular diagnostics solutions.
The company offers nProfiler1 Expansion Stomach Cancer Assay to analyze the gene expression profiles of stage II-III gastric cancer.
It also provides nProfiler 2, a cancer variant assay; AI assisted digital pathology and auto sampling system; nProfiler, a breast cancer assay; nProfiler, a colon cancer assay; nProfiler, a rectal cancer assay; and nProfiler, a cOVID-19 detection kit.
The company was formerly known as Novomics Meditech Co., Ltd. and changed its name to Novomics Co., Ltd. in July 2015.
Novomics Co., Ltd. was founded in 2010 and is based in Seoul, South Korea.
Novomics Co., Ltd.
| Country | South Korea |
| Founded | 2010 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
Contact Details
Address: 304,305,306,306-1 KeumKang Penterium IT Tower Seoul, 07217 South Korea | |
| Phone | 82 2 2068 3700 |
| Website | novomics.com |
Stock Details
| Ticker Symbol | 283100 |
| Exchange | Korea New Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2835 |